Bloomington, Ind. – Just weeks after 2015 country approval of Cook Medical’s Zenith Alpha™ Abdominal Endovascular Graft, the University of Western London Health Sciences Centre in London, Ontario treated the first patient with the device as part of Cook’s Canada commercial launch.
“We would like to the thank Cook for the opportunity to place the first Cook Alpha AAA endograft in North America,” said Adam Power, MD, assistant professor and program director of vascular surgery at University of Western London Health Sciences Centre following 2015 approval. “We are proud of our aortic experience here at Western University and this case enables us to continue pushing innovative approaches to aortic pathology for the best treatment of our patients.”
Zenith Alpha Abdominal is indicated for endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having vascular anatomy suitable for endovascular repair . These indications are aligned with the terms of market authorization.
The introduction system features an ergonomic design and requires fewer procedural steps than previous designs to deploy the device without sacrificing the precision and control of the Zenith platform. The device also allows for wider patient applicability because of its lower profile introduction system, three-piece modular design and broad range of sizes.
“Zenith Alpha Abdominal Canadian approval and its first commercial use is an exciting step in Cook Medical’s mission to provide physicians around the world with disease-specific treatment options,” said Nicky James, vice president and global business unit leader for Cook Medical’s Aortic Intervention division. “The lower profile device is designed to help physicians provide the benefits of endovascular repair to more patients.”
For more information about Zenith Alpha Abdominal and other Aortic Intervention products, visit cookmedical.com/aortic-intervention. Follow us on Twitter @CookEVAR.
Dr. Power is a paid consultant of Cook Medical.